BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zero Infections in High-Risk Cardiac Device Replacements Reported With Use of TYRX Antibacterial Envelope


6/26/2013 11:22:04 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ATHENS, Greece--(BUSINESS WIRE)--Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope reduced major infection rates by 100% in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacement procedures compared to case-matched retrospective control patients. Investigators presented new interim results from the Citadel / Centurion Clinical Study today at the Late Breaking Clinical Trials session at the European Heart Rhythm Association (EHRA), EUROPACE 2013. The Citadel / Centurion study is a prospective, multicenter clinical study in patients at high-risk for CIED infection who have their CIED implanted with the AIGISRx Antibacterial Envelope. The aim of the study is to evaluate the impact of the AIGISRx Antibacterial Envelope on major device infection and mechanical complication rates in the 12-months after implantation. Investigators at 55 US centers enrolled patients who were at high-risk for device infection because they were undergoing a CIED replacement procedure with either an implantable cardioverter-defibrillator (ICD), (Citadel), or a cardiac resynchronization therapy (CRT) device (Centurion).

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

TYRX
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES